Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced-dose TBI/cyclophosphamide versus fludarabine/melphalan conditioning for allogeneic transplant in adults with ALL in remission
2017-004800-23Phase 2Unknown
- Sponsor
- University of Birmingham
- Start
- Aug 2018
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of cyclophosphamide, fludarabine and melphalan in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by University of Birmingham. Primary endpoint: Disease-free survival. Status: unknown.
02
Drugs
cyclophosphamidefludarabinemelphalan
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2017-004800-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004800-23.